ObjectiveTo investigate the point prevalence rate of nosocomial infection and discover the problems in the management of nosocomial infection.MethodsA team of surveyors were trained to collect necessary data of inpatients on a single day. Questionnaires about nosocomial infection cases were filled out and analysed.Results492 patients were investigated, 31 patients developed into nosocomial infection, the point prevalence rate was 6.30%. The point prevalence rate of nosocomial infection in ICU was 57%; The main infectious site was urinary tract. ConclusionThe survey on the point prevalence rate is beneficial to manage nosocomial infection.

With the aggravation of enviromental pollution, a quickly, sensitive, inexpensive monitoring means should be developed to protect water resources. Luminescent bacteria as biosensor have the advantages mentioned above. During past two decades, luminescent bacteria toxicity test was used widely in comprehensive toxicity evaluation, screening, monitoring and specific pollutants detection in water, the recent progress in this field was reviewed in this paper.

Brown-Sequard Syndrome ; etiology ; Cervical Vertebrae ; Humans ; Intervertebral Disc Displacement ; complications ; surgery ; Male ; Middle Aged

Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Cisplatin ; administration & dosage ; Deoxycytidine ; administration & dosage ; analogs & derivatives ; Female ; Humans ; Lymphoma, T-Cell ; drug therapy ; pathology ; Male ; Methylprednisolone Hemisuccinate ; administration & dosage ; Middle Aged ; Neoplasm Recurrence, Local ; drug therapy ; Remission Induction

Objective To study the possible relationships between expression of matrix metalloproteinase(MMP)2,9 and the pathogenesis of preeclampsia in which trophoblast invasion is impaired. Methods MMP-2,9 expression were detected by immunohistochemistry streptavidin-biotin complex (SABC)method in 20 normal term placentae and 20 preeclampsia placentae,respectively.In addition, mRNAs for MMP-2,9 were analyzed by real time PCR in both groups.Results The intensities of both MMP-2 and MMP-9 immunostaining in preeclampsia placentae were significantly declined compared to those of normal term placentae(P

Objective To study the effect of puerarin on the nitrogen monoxide(NO) concentration in rats with pre-eclampsia. Methods Thirty SD rats were selected and divided into three groups: normal pregnancy group, pre-eclampsia model group and puerarin group(10 rats in each group). We used endotoxin to set up the pre-eclampsia model rats on gestation 14th day and puerarin to treat these rats. The 24 hour urine protein on gestation 8th,15th,19th days were determined, as well as the heart rate, blood pressure on gestation 10th,15th,19th days. Nitrate reductase method was used to determine the plasma NO concentration of each group on gestation 21st day. Results (1) There was significant difference in urine protein concentration between the puerarin [(73 ? 20) ?g],pre-eclampsia [ (464 ? 57)?g], and normal pregnancy [(140 ? 12)?g], groups (which is equal to the value of urine protein of pregnancy 19th day subtracting that of pregnancy 8th day, P0.05).(4)There was significant difference in NO concentration (NO concentration at gestation 19th day subtracting that of 8th day) between the three groups(P

Objective To evaluate whether estradiol can inhibit and cure the inflammation of experimental preeclampsia in rats. Methods Experimental preeclampsia was induced in 14-day-pregnant rats by infusion of endotoxin (1.0 ?g/kg). Rats with normal pregnancy were infused with sodium chloride solution.A group of preeclampsia rats was injected with 17?-estradiol (17?-E_2, 1 mg?kg -1 ?d -1 ). Blood pressure, albuminuria,inflammation associated adhesion molecule CD_ 49d and tumor necrosis factor-?(TNF-?) were assessed. Results On pregnant day 19, for normal pregnancy group(group C) the blood pressure was (120.4?2.0)mm Hg (1 mm Hg=0.133 kPa),urinary protein (0.47?0.06)mg/24 hours;for experimental preeclampsia group(group A) blood pressure was (134.2?2.4) mm Hg,urinary protein(0.79?0.10)mg/24 hours; for experimental preeclampsia with 17?-E_2 treatment group (group B) blood pressure was(123.3?1.7)mm Hg,urinary protein (0.51?0.08)mg/24 hours. A significant increase of blood pressure and urinary albumin was observed in group A. CD_ 49d expression and TNF-? concentration were also increased. 17?-E_2 reduced the expression of CD_ 49d , concentration of TNF-?,blood pressure and albuminuria of experimental preeclampsia. However, the weight of fetuses in 17?-E_2 treatment group were less than that in other groups. Conclusion 17?-E_2 can improve the symptoms of experimental preeclampsia,but its effects on fetus need to be further studied.

The interindividual genetic variations in drug metabolizing enzymes and transporters influence the efficacy and toxicity of numerous drugs. As a fundamental element in precision med-icine, pharmacogenomics, the study of responses of individuals to medication based on their genomic information, enables the evaluation of some specific genetic variants responsible for an individual’s particular drug response. In this article, we review the contributions of genetic polymorphisms to major individual variations in drug pharmacotherapy, focusing specifically on the pharmacoge-nomics of phase-I drug metabolizing enzymes and transporters. Substantial frequency differences in key variants of drug metabolizing enzymes and transporters, as well as their possible functional consequences, have also been discussed across geographic regions. The current effort illustrates the common presence of variability in drug responses among individuals and across all geographic regions. This information will aid health-care professionals in prescribing the most appropriate treatment aimed at achieving the best possible beneficial outcomes while avoiding unwanted effects for a particular patient.

Animals ; Carcinogens ; toxicity ; Female ; Lung Neoplasms ; chemically induced ; pathology ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Mice, Inbred Strains ; Sensitivity and Specificity ; Urethane ; toxicity

Vaccination is the primary strategy for the prevention and control of pandemic influenza. Because influenza virus is highly variable across strains, universal influenza vaccines need to be developed to address this problem. This review describes the research progress in conserved epitopes of influenza virus, the advances in the research and development of universal influenza vaccines based on the relatively conserved sequences of NP, M2e, HA2, and headless HA, the mechanisms of cross-protection, and the methods to improve cross-protection.
Animals ; Cross Reactions ; Humans ; Orthomyxoviridae ; immunology ; Species Specificity ; Viral Proteins ; immunology ; Viral Vaccines ; genetics ; immunology